Valeant Pharmaceuticals (VRX) gains on Q2 results

Valeant Pharmaceuticals International, Inc.

shares climbed 3.9% to $248.24 on announcing second-quarter financial results. Total revenue was $2.7 billion; an increase of 34% over the prior year. Operating income was $341.5 million, down from $355.1 million in the prior-year quarter. Share volume was 99,000, compared to an all-day average of 270,000